Abstract
Background Chest CT examination is significant in COVID-19 diagnosis due to its high sensitivity. Although typical chest CT findings have been discussed thoroughly in the literature throughout the pandemic, we aimed to investigate the prevalence of the atypical conclusions during the start of the Omicron variant insurgency and compare the results to studies conducted before its outbreak.
Methods 606 confirmed COVID-19 cases were included in this study based on inclusion and exclusion criteria during January and February 2022. Demographic information of patients, including age and sex, was recorded. The computed tomography (CT) examination was carried out using a 100-slice scanner (Philips Brilliance 6 CT Scanner). One radiology attending and one resident evaluated SARS-CoV-2 RT-PCR-positive patients for atypical pulmonary CT findings. The obtained data were evaluated using R software version 4.1.1.
Results 55% of patients were female, and the median age was 56 (IQR: 42, 69) 59% of patients had atypical findings on their pulmonary CT examination. These findings showed that pleural abnormalities were the most frequent atypical findings, with pleural thickening being the most common (17%). The double halo sign represented the least frequent atypical sign (0.2%).
Conclusion Atypical findings were more prevalent in this study than its predecessors, while we acknowledge that other factors, such as study design and patient population, could have impacted it. The presence of atypical signs generally was not correlated with specific demographic groups, while some of these signs were more frequent in some groups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Iran National Committee for Ethics in Biomedical Research approved this study with the ethics code of IR.ZUMS.REC.1401.175
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
soheilaborji61{at}zums.ac.ir
Pouriaisavand{at}gmail.com
mobinaz98{at}yahoo.com
Ehsanghafouri.md{at}gmail.com
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- COVID-19
- Coronavirus disease 2019
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- SARS-CoV-1
- Severe Acute Respiratory Syndrome coronavirus-1
- RT-PCR
- Reverse transcription polymerase chain reaction
- CT-scan
- Computed tomography scan
